Drug · CHEMBL1237119
TREPROSTINIL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TREPROSTINIL. Drugs and targets, record CHEMBL1237119. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1237119
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 15-AU-81, 15AU81, L-606, L606, LRX -15, LRX-15, Rumodolin, Treprostinilo, Tresprostinil, UT-15, Uniprost
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 18 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PTGIR | Prostacyclin receptor | Prostanoid IP receptor agonist | AGONIST | https://conductscience.org/library/genes/5739 |
Source ChEMBL
Diseases18
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| pulmonary arterial hypertension | Approval | DailyMed, PMDA and TTD | 48 | 41 | https://conductscience.org/library/drugs?q=MONDO_0015924 |
| pulmonary hypertension | Approval | EMA Human Drugs | 21 | 19 | https://conductscience.org/library/drugs?q=MONDO_0005149 |
| chronic obstructive pulmonary disease | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005002 |
| idiopathic pulmonary fibrosis | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=EFO_0000768 |
| interstitial lung disease | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0015925 |
| pulmonary fibrosis | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0002771 |
| systemic sclerosis | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005100 |
| Exercise intolerance | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0003546 |
| Hypoxemia | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0012418 |
| Pulmonary arterial hypertension associated with portal hypertension | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0009197 |
1 to 10 of 18Source Open Targets
See all 18 diseasesTrials96
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01027949 | An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension | Phase 3 | 894 | 2021-05-10 | treprostinil | Its name | ClinicalTrials.gov |
| NCT00325442 | FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) | Phase 3 | 354 | 2013-06-10 | treprostinil | Its name | ClinicalTrials.gov |
| NCT00325403 | FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) | Phase 3 | 349 | 2013-03-18 | treprostinil | Its name | ClinicalTrials.gov |
| NCT02630316 | Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE | Phase 2/3 | 326 | 2021-07-13 | treprostinil | Its name | ClinicalTrials.gov |
| NCT00887978 | Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension | Phase 3 | 310 | 2013-01-15 | treprostinil | Its name | ClinicalTrials.gov |
| NCT02633293 | An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE | Phase 2/3 | 243 | 2022-12-02 | treprostinil | Its name | ClinicalTrials.gov |
| NCT00147199 | Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) | Phase 3 | 235 | 2013-08-12 | treprostinil | Its name | ClinicalTrials.gov |
| NCT03496623 | A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | 188 | 2023-11-24 | treprostinil | Its name | ClinicalTrials.gov |
| NCT03399604 | Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil | Phase 3 | 121 | 2024-07-30 | treprostinil | Its name | ClinicalTrials.gov |
| NCT03037580 | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction | Phase 3 | 84 | 2020-10-22 | treprostinil | Its name | ClinicalTrials.gov |
1 to 10 of 96
See all 96 trialsComparisons in its trials33
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tyvaso vs Control: serious adverse events | 96 of 666 | 94 of 667 | 1,333 | NCT01266265 | Trial comparisons |
| Active vs Placebo Arm: Clinical Worsening Assessment | 8 of 174 | 12 of 176 | 350 | NCT00325442 | Trial comparisons |
| Active vs Placebo Arm: serious adverse events | 32 of 174 | 33 of 176 | 350 | NCT00325442 | Trial comparisons |
| Inhaled Treprostinil vs Placebo: Incidence of Clinical Worsening | 37 of 163 | 54 of 163 | 326 | NCT02630316 | Trial comparisons |
| Active Inhaled Treprostinil vs Placebo: deaths from any cause | 10 of 163 | 12 of 163 | 326 | NCT02630316 | Trial comparisons |
| Active Inhaled Treprostinil vs Placebo: serious adverse events | 38 of 163 | 42 of 163 | 326 | NCT02630316 | Trial comparisons |
| UT-15C SR vs Placebo: serious adverse events | 23 of 157 | 23 of 153 | 310 | NCT00887978 | Trial comparisons |
| LIQ861 Add-On vs Tyvaso Transition: deaths from any cause | 0 of 121 | 0 of 121 | 242 | NCT03399604 | Trial comparisons |
| LIQ861 Add-On vs Tyvaso Transition: serious adverse events | 15 of 121 | 6 of 121 | 242 | NCT03399604 | Trial comparisons |
| Inhaled Treprostinil vs Placebo: serious adverse events | 9 of 115 | 13 of 120 | 235 | NCT00147199 | Trial comparisons |
1 to 10 of 33
See all 33 comparisons in its trialsPapers from its trials30
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 24431095 | RESULT | 1 | PubMed |
| 42972641 | DERIVED | 2 | PubMed |
| 42776606 | DERIVED | 2 | PubMed |
| 42548323 | DERIVED | 1 | PubMed |
| 42149993 | DERIVED | 1 | PubMed |
| 41812190 | DERIVED | 1 | PubMed |
| 41627369 | DERIVED | 2 | PubMed |
| 40882760 | DERIVED | 1 | PubMed |
| 38811045 | DERIVED | 1 | PubMed |
| 37532157 | DERIVED | 1 | PubMed |
1 to 10 of 30
See all 30 papers from its trialsTests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1237119
GET https://conductscience.org/api/drugs/v1/CHEMBL1237119/trials?page=2